Microbot Medical (MBOT) & Novavax (NVAX) Head to Head Analysis

Microbot Medical (NASDAQ: MBOT) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Volatility & Risk

Microbot Medical has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500.

Profitability

This table compares Microbot Medical and Novavax’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Microbot Medical N/A -48.95% -46.46%
Novavax -529.93% N/A -58.74%

Valuation and Earnings

This table compares Microbot Medical and Novavax’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Microbot Medical $120,000.00 287.82 -$7.58 million N/A N/A
Novavax $31.18 million 19.83 -$183.76 million ($0.63) -2.57

Microbot Medical has higher earnings, but lower revenue than Novavax.

Analyst Recommendations

This is a summary of current ratings and price targets for Microbot Medical and Novavax, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical 0 0 1 0 3.00
Novavax 1 3 4 0 2.38

Microbot Medical presently has a consensus price target of $1.75, indicating a potential upside of 113.41%. Novavax has a consensus price target of $3.51, indicating a potential upside of 116.82%. Given Novavax’s higher probable upside, analysts clearly believe Novavax is more favorable than Microbot Medical.

Insider and Institutional Ownership

5.1% of Microbot Medical shares are owned by institutional investors. Comparatively, 40.5% of Novavax shares are owned by institutional investors. 31.8% of Microbot Medical shares are owned by insiders. Comparatively, 3.4% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Microbot Medical Company Profile

Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. It also holds an intellectual property portfolio that comprises 9 patent families, which include 9 patents granted in the United States, 12 patents granted outside the United States, and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.

Novavax Company Profile

Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply